Actuate Therapeutics Inc

Actuate Therapeutics Inc (ACTU) Market Cap

Actuate Therapeutics Inc has a market capitalization of $65.9M.

Financials based on reported quarter end 2025-12-31

Price: $2.78

โ–ฒ 0.52 (22.74%)

Market Cap: 65.91M

NASDAQ ยท time unavailable

CEO: Daniel Schmitt

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2024-08-13

Website: https://actuatetherapeutics.com

Actuate Therapeutics Inc (ACTU) - Company Information

Market Cap: 65.91M ยท Sector: Healthcare

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Analyst Sentiment

83%
Strong Buy

Based on 1 ratings

Analyst 1Y Forecast: $0.00

Average target (based on 1 sources)

Consensus Price Target

Low

$21

Median

$21

High

$21

Average

$21

Potential Upside: 655.4%

Price & Moving Averages

Loading chart...

Fundamentals Overview

Loading fundamentals overview...

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"ACTU reported revenue of $0 and net income of -$4.6m (EPS: -$0.20) for the quarter ended 2025-12-31. Net margin was negative, and operating cash flow was -$3.7m, producing free cash flow of -$3.7m. Balance sheet figures show total assets of $14.0m versus total liabilities of $6.1m, leaving equity of $7.9m. Net debt is negative (-$12.8m), indicating the company is in a net cash position rather than levered debt. From a cash-flow quality perspective, results are currently dominated by cash burn: operating cash flow and free cash flow are both materially negative, and dividends are $0. With no buyback information provided, shareholder returns are primarily tied to share price performance, which has been weak: the stock is down -71.0% over 1 year and -62.0% YTD, suggesting the market has continued to reassess prospects. Valuation context is limited because market cap and revenue are not provided, and the company is loss-making, so P/E and FCF yield cannot be meaningfully assessed from the supplied inputs. Analyst price targets cluster at $21, but the current price of $2.29 implies the market price is far below those targets."

Revenue Growth

Neutral

Revenue is reported as $0 for the period, preventing assessment of growth or demand drivers.

Profitability

Neutral

Net income is -$4.6m with EPS of -$0.20, indicating sustained losses and no evidence of operating profitability in the provided quarter.

Cash Flow Quality

Neutral

Operating cash flow of -$3.7m and free cash flow of -$3.7m point to ongoing cash burn; dividends are $0 and no buybacks are provided.

Leverage & Balance Sheet

Neutral

Net debt is -$12.8m (net cash position). Assets of $14.0m exceed liabilities of $6.1m, with equity of $7.9m supporting resilience despite losses.

Shareholder Returns

Neutral

Total shareholder return appears weak given large capital depreciation: -71% 1-year and -66% 6-month declines, with no dividends and no buyback data to offset price weakness.

Analyst Sentiment & Valuation

Neutral

Consensus price target is $21 versus a current price of $2.29, but the company is loss-making with revenue shown as $0, limiting traditional valuation interpretation.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
๐Ÿ“

SEC Filings (ACTU)

ยฉ 2026 Stock Market Info โ€” Actuate Therapeutics Inc (ACTU) Financial Profile